MX2017006491A - Composiciones y métodos para la modulación de la actividad at2r. - Google Patents

Composiciones y métodos para la modulación de la actividad at2r.

Info

Publication number
MX2017006491A
MX2017006491A MX2017006491A MX2017006491A MX2017006491A MX 2017006491 A MX2017006491 A MX 2017006491A MX 2017006491 A MX2017006491 A MX 2017006491A MX 2017006491 A MX2017006491 A MX 2017006491A MX 2017006491 A MX2017006491 A MX 2017006491A
Authority
MX
Mexico
Prior art keywords
methods
at2r
activity
compositions
modulating
Prior art date
Application number
MX2017006491A
Other languages
English (en)
Inventor
R Srinivas Raja
P Gavini Madhavi
Original Assignee
Novopyxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novopyxis Inc filed Critical Novopyxis Inc
Publication of MX2017006491A publication Critical patent/MX2017006491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Abstract

Se divulgan nuevos agonistas de polipéptido de AT2R, así como composiciones farmacéuticas que comprenden los agonistas, métodos de su uso en el tratamiento de enfermedades, padecimientos o trastornos caracterizados por la actividad de AT2R insuficiente o la actividad de AT1R excesiva, y métodos de su uso como reactivos de laboratorio para propósitos de investigación.
MX2017006491A 2014-11-19 2015-11-19 Composiciones y métodos para la modulación de la actividad at2r. MX2017006491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081839P 2014-11-19 2014-11-19
PCT/US2015/061597 WO2016081733A2 (en) 2014-11-19 2015-11-19 Compositions and methods for modulating at2r activity

Publications (1)

Publication Number Publication Date
MX2017006491A true MX2017006491A (es) 2018-02-13

Family

ID=56014682

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006491A MX2017006491A (es) 2014-11-19 2015-11-19 Composiciones y métodos para la modulación de la actividad at2r.

Country Status (10)

Country Link
US (2) US10105411B2 (es)
EP (1) EP3220940B1 (es)
JP (2) JP6934814B2 (es)
AU (2) AU2015349863B2 (es)
CA (1) CA2968053A1 (es)
ES (1) ES2892957T3 (es)
IL (1) IL252191B (es)
MX (1) MX2017006491A (es)
RU (1) RU2721241C2 (es)
WO (1) WO2016081733A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017006491A (es) 2014-11-19 2018-02-13 Novopyxis Inc Composiciones y métodos para la modulación de la actividad at2r.
WO2019238962A1 (en) * 2018-06-14 2019-12-19 University College Cork - National University Of Ireland, Cork Peptide for disease treatment
WO2020000469A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 促进 at2r 蛋白过表达的重组载体及其构建方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO981397A0 (en) * 1997-10-15 1997-11-06 Garvan Institute Of Medical Research Novel npy family member
US7173011B2 (en) * 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2006073772A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US8362325B2 (en) * 2007-10-03 2013-01-29 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
US9029636B2 (en) * 2008-02-05 2015-05-12 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
CN102272163A (zh) * 2008-12-05 2011-12-07 安吉奥开米公司 瘦素和瘦素类似物结合物及其用途
FR2943346B1 (fr) * 2009-03-19 2011-05-06 Univ Paris Curie Peptides modulant l'activite de l'igf-1 et leurs applications
US11512326B2 (en) * 2009-05-26 2022-11-29 University Of Florida Research Foundation, Incorporated Small angiotensin peptide expression system in mammalian cells
US8835471B2 (en) * 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP2455388A1 (en) * 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
RU2472471C1 (ru) * 2011-11-24 2013-01-20 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации Способ снижения внутриглазного давления
US20150119329A1 (en) * 2012-04-16 2015-04-30 New York University Modulation of angiotensin ii receptors for the prevention and treatment of malaria cerebral
MX2017006491A (es) 2014-11-19 2018-02-13 Novopyxis Inc Composiciones y métodos para la modulación de la actividad at2r.

Also Published As

Publication number Publication date
EP3220940B1 (en) 2021-07-21
RU2721241C2 (ru) 2020-05-18
JP2017536415A (ja) 2017-12-07
IL252191A0 (en) 2017-07-31
US20170304390A1 (en) 2017-10-26
ES2892957T3 (es) 2022-02-07
JP2021130704A (ja) 2021-09-09
WO2016081733A2 (en) 2016-05-26
US10105411B2 (en) 2018-10-23
RU2017121091A3 (es) 2019-06-05
EP3220940A4 (en) 2018-10-03
US10675324B2 (en) 2020-06-09
IL252191B (en) 2022-03-01
US20190000916A1 (en) 2019-01-03
RU2017121091A (ru) 2018-12-19
WO2016081733A3 (en) 2016-07-28
CA2968053A1 (en) 2016-05-26
EP3220940A2 (en) 2017-09-27
AU2015349863A1 (en) 2017-06-01
AU2015349863B2 (en) 2021-09-09
JP6934814B2 (ja) 2021-09-15
AU2021221858A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
AU2024202345A1 (en) Nucleic acid carriers and therapeutic methods of use
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MY187540A (en) Compounds active towards bromodomains
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MY199091A (en) Therapeutic compounds
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2020000135A (es) Nuevos compuestos de quinolinona.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use